Bone morphogenetic protein and bone metastasis, implication and therapeutic potential

Frontiers in Bioscience

Volumn 16, Issue 3, 2011, Pages 865-897

  Ye, Lin ^a   Mason, Malcolm D ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

BMP; Bone metastasis; Bone morphogenetic protein; Review; Smad

Indexed keywords

ANDROGEN; BAMBI PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR; ESTROGEN RECEPTOR; MEMBRANE PROTEIN; SMAD PROTEIN;

APOPTOSIS; BONE TUMOR; BREAST TUMOR; CANCER INVASION; CELL MOTION; CELL PROLIFERATION; DNA METHYLATION; DRUG ANTAGONISM; DRUG EFFECT; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENETICS; HUMAN; LUNG TUMOR; MALE; METABOLISM; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); OSTEOBLAST; OSTEOLYSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; REVIEW; SIGNAL TRANSDUCTION;

ANDROGENS; APOPTOSIS; BONE MORPHOGENETIC PROTEIN RECEPTORS; BONE MORPHOGENETIC PROTEINS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; DNA METHYLATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOBLASTS; OSTEOLYSIS; PROSTATIC NEOPLASMS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; SMAD PROTEINS;

EID: 79955045027     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3725     Document Type: Article

References (331)

1. K.R. Hess, G.R. Varadhachary, S.H. Taylor, W. Wei, M.N. Raber, R. Lenzi, and J.L. Abbruzzese: Metastatic patterns in adenocarcinoma. Cancer 106, 1624-1633 (2006)
2. G.R. Mundy: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2, 584-593 (2002) (Pubitemid 37328925)
3. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun: Cancer statistics, 2009. CA Cancer J Clin 59, 225-249 (2009)
4. M.P. Roudier, C. Morrissey, L.D. True, C.S. Higano, R.L. Vessella, and S.M. Ott: Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 180, 1154-1160 (2008)
5. Y. Du, I. Cullum, T.M. Illidge, and P.J. Ell: Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol 25, 3440-3447 (2007) (Pubitemid 47310881)
6. M.S. Bendre, A.G. Margulies, B. Walser, N.S. Akel, S. Bhattacharrya, R.A. Skinner, F. Swain, V. Ramani, K.S. Mohammad, L.L. Wessner, A. Martinez, T.A. Guise, J.M. Chirgwin, D. Gaddy, and L.J. Suva: Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 65, 11001-11009 (2005) (Pubitemid 41713370)
7. S.M. Kakonen, K.S. Selander, J.M. Chirgwin, J.J. Yin, S. Burns, W.A. Rankin, B.G. Grubbs, M. Dallas, Y. Cui, and T.A. Guise: Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 277, 24571-24578 (2002) (Pubitemid 34951984)
8. J.J. Yin, K. Selander, J.M. Chirgwin, M. Dallas, B.G. Grubbs, R. Wieser, J. Massague, G.R. Mundy, and T.A. Guise: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103, 197-206 (1999) (Pubitemid 29053137)
9. O. Kudo, A. Sabokbar, A. Pocock, I. Itonaga, Y. Fujikawa, and N.A. Athanasou: Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32, 1-7 (2003) (Pubitemid 36173806)
10. J.J. Yin, C.B. Pollock, and K. Kelly: Mechanisms of cancer metastasis to the bone. Cell Res 15, 57-62 (2005) (Pubitemid 41653967)
11. T. Yoneda and T. Hiraga: Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328, 679-687 (2005) (Pubitemid 40208305)
12. M.R. Urist: Bone: formation by autoinduction. Science 150, 893-899 (1965)
13. J.M. Wozney, V. Rosen, A.J. Celeste, L.M. Mitsock, M.J. Whitters, R.W. Kriz, R.M. Hewick, and E.A. Wang: Novel regulators of bone formation: molecular clones and activities. Science 242, 1528-1534 (1988) (Pubitemid 19023695)
14. A.J. Celeste, J.A. Iannazzi, R.C. Taylor, R.M. Hewick, V. Rosen, E.A. Wang, and J.M. Wozney: Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. Proc Natl Acad Sci U S A 87, 9843-9847 (1990) (Pubitemid 120016540)
15. S.J. Lee: Identification of a novel member (GDF-1) of the transforming growth factor-beta superfamily. Mol Endocrinol 4, 1034-1040 (1990)
16. E. Ozkaynak, D.C. Rueger, E.A. Drier, C. Corbett, R.J. Ridge, T.K. Sampath, and H. Oppermann: OP-1 cDNA encodes an osteogenic protein in the TGF-beta family. Embo J 9, 2085-2093 (1990)
17. J.M. Wozney, V. Rosen, M. Byrne, A.J. Celeste, I. Moutsatsos, and E.A. Wang: Growth factors influencing bone development. J Cell Sci Suppl 13, 149-156 (1990)
18. S.J. Butler and J. Dodd: A role for BMP heterodimers in roof plate-mediated repulsion of commissural axons. Neuron 38, 389-401 (2003) (Pubitemid 36579142)
19. Y. Cui, F. Jean, G. Thomas, and J.L. Christian: BMP-4 is proteolytically activated by furin and/or PC6 during vertebrate embryonic development. Embo J 17, 4735-4743 (1998) (Pubitemid 28377173)
20. D.B. Constam and E.J. Robertson: Regulation of bone morphogenetic protein activity by pro domains and proprotein convertases. J Cell Biol 144, 139-149 (1999) (Pubitemid 29047017)
21. A. Tsuji, E. Hashimoto, T. Ikoma, T. Taniguchi, K. Mori, M. Nagahama, and Y. Matsuda: Inactivation of proprotein convertase, PACE4, by alpha1-antitrypsin Portland (alpha1-PDX), a blocker of proteolytic activation of bone morphogenetic protein during embryogenesis: evidence that PACE4 is able to form an SDS-stable acyl intermediate with alpha1-PDX. J Biochem (Tokyo) 126, 591-603 (1999) (Pubitemid 29452626)
22. O. Hashimoto, R.K. Moore, and S. Shimasaki: Posttranslational processing of mouse and human BMP-15: potential implication in the determination of ovulation quota. Proc Natl Acad Sci U S A 102, 5426-5431 (2005) (Pubitemid 40530274)
23. S. Mazerbourg and A.J. Hsueh: Genomic analyses facilitate identification of receptors and signaling pathways for growth differentiation factor 9 and related orphan bone morphogenetic protein/growth differentiation factor ligands. Hum Reprod Update 12, 373-383 (2006) (Pubitemid 43923412)
24. S.J. Lee and A.C. McPherron: Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A 98, 9306-9311 (2001) (Pubitemid 32743912)
25. M.A. Brown, Q. Zhao, K.A. Baker, C. Naik, C. Chen, L. Pukac, M. Singh, T. Tsareva, Y. Parice, A. Mahoney, V. Roschke, I. Sanyal, and S. Choe: Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J Biol Chem 280, 25111-25118 (2005) (Pubitemid 40934603)
26. A. Aono, M. Hazama, K. Notoya, S. Taketomi, H. Yamasaki, R. Tsukuda, S. Sasaki, and Y. Fujisawa: Potent ectopic bone-inducing activity of bone morphogenetic protein-4/7 heterodimer. Biochem Biophys Res Commun 210, 670-677 (1995)
27. D.I. Israel, J. Nove, K.M. Kerns, R.J. Kaufman, V. Rosen, K.A. Cox, and J.M. Wozney: Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and in vivo. Growth Factors 13, 291-300 (1996) (Pubitemid 26378947)
28. A. Suzuki, E. Kaneko, J. Maeda, and N. Ueno: Mesoderm induction by BMP-4 and -7 heterodimers. Biochem Biophys Res Commun 232, 153-156 (1997) (Pubitemid 27211938)
29. L. Ye, J.M. Lewis-Russell, H.G. Kyanaston, and W.G. Jiang: Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol Histopathol 22, 1129-1147 (2007) (Pubitemid 47470307)
30. J.L. Wrana, L. Attisano, R. Wieser, F. Ventura, and J. Massague: Mechanism of activation of the TGF-beta receptor. Nature 370, 341-347 (1994) (Pubitemid 2110860)
31. L. Attisano, J.L. Wrana, F. Lopez-Casillas, and J. Massague: TGF-beta receptors and actions. Biochim Biophys Acta 1222, 71-80 (1994) (Pubitemid 2090633)
32. J. Greenwald, W.H. Fischer, W.W. Vale, and S. Choe: Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase. Nat Struct Biol 6, 18-22 (1999) (Pubitemid 29232418)
33. T. Kirsch, W. Sebald, and M.K. Dreyer: Crystal structure of the BMP-2-BRIA ectodomain complex. Nat Struct Biol 7, 492-496 (2000) (Pubitemid 30414472)
34. J.L. Wrana, H. Tran, L. Attisano, K. Arora, S.R. Childs, J. Massague, and M.B. O'Connor: Two distinct transmembrane serine/threonine kinases from Drosophila melanogaster form an activin receptor complex. Mol Cell Biol 14, 944-950 (1994) (Pubitemid 24036544)
35. P.D. Mace, J.F. Cutfield, and S.M. Cutfield: High resolution structures of the bone morphogenetic protein type II receptor in two crystal forms: implications for ligand binding. Biochem Biophys Res Commun 351, 831-838 (2006) (Pubitemid 44715860)
36. A. Moustakas and C.H. Heldin: From mono- to oligo-Smads: the heart of the matter in TGF-beta signal transduction. Genes Dev 16, 1867-1871 (2002) (Pubitemid 34832916)
37. A. Nohe, S. Hassel, M. Ehrlich, F. Neubauer, W. Sebald, Y.I. Henis, and P. Knaus: The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 277, 5330-5338 (2002) (Pubitemid 34968578)
38. A. Nohe, E. Keating, P. Knaus, and N.O. Petersen: Signal transduction of bone morphogenetic protein receptors. Cell Signal 16, 291-299 (2004) (Pubitemid 37542404)
39. C.H. Heldin, K. Miyazono, and P. ten Dijke: TGF-beta signaling from cell membrane to nucleus through SMAD proteins. Nature 390, 465-471 (1997) (Pubitemid 28013118)
40. Y. Shi and J. Massague: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685-700 (2003) (Pubitemid 36724933)
41. M. Kretzschmar and J. Massague: SMADs: mediators and regulators of TGF-beta signaling. Curr Opin Genet Dev 8, 103-111 (1998) (Pubitemid 28122148)
42. H. Jornvall, A. Blokzijl, P. ten Dijke, and C.F. Ibanez: The orphan receptor serine/threonine kinase ALK7 signals arrest of proliferation and morphological differentiation in a neuronal cell line. J Biol Chem 276, 5140-5146 (2001)
43. Y.G. Chen and J. Massague: Smad1 recognition and activation by the ALK1 group of transforming growth factor-beta family receptors. J Biol Chem 274, 3672-3677 (1999) (Pubitemid 29077212)
44. L. Attisano and S.T. Lee-Hoeflich: The Smads. Genome Biol 2, REVIEWS3010 (2001)
45. W. Chen, X. Fu, and Z. Sheng: Review of current progress in the structure and function of Smad proteins. Chin Med J (Engl) 115, 446-450 (2002)
46. M. Kretzschmar, J. Doody, I. Timokhina, and J. Massague: A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev 13, 804-816 (1999) (Pubitemid 29169840)
47. Y. Zhang, C. Chang, D.J. Gehling, A. Hemmati-Brivanlou, and R. Derynck: Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci U S A 98, 974-979 (2001) (Pubitemid 32121172)
48. K. Miyazawa, M. Shinozaki, T. Hara, T. Furuya, and K. Miyazono: Two major Smad pathways in TGF-beta superfamily signaling. Genes Cells 7, 1191-1204 (2002) (Pubitemid 36024597)
49. T. Tsukazaki, T.A. Chiang, A.F. Davison, L. Attisano, and J.L. Wrana: SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 95, 779-791 (1998) (Pubitemid 29014458)
50. K. Kusanagi, H. Inoue, Y. Ishidou, H.K. Mishima, M. Kawabata, and K. Miyazono: Characterization of a bone morphogenetic protein-responsive Smad-binding element. Mol Biol Cell 11, 555-565 (2000) (Pubitemid 30112165)
51. Y. Shi, Y.F. Wang, L. Jayaraman, H. Yang, J. Massague, and N.P. Pavletich: Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell 94, 585-594 (1998) (Pubitemid 28427577)
52. H. Shibuya, K. Yamaguchi, K. Shirakabe, A. Tonegawa, Y. Gotoh, N. Ueno, K. Irie, E. Nishida, and K. Matsumoto: TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 272, 1179-1182 (1996)
53. K. Yamaguchi, S. Nagai, J. Ninomiya-Tsuji, M. Nishita, K. Tamai, K. Irie, N. Ueno, E. Nishida, H. Shibuya, and K. Matsumoto: XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. Embo J 18, 179-187 (1999) (Pubitemid 29005034)
54. K. Yamaguchi, K. Shirakabe, H. Shibuya, K. Irie, I. Oishi, N. Ueno, T. Taniguchi, E. Nishida, and K. Matsumoto: Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 270, 2008-2011 (1995) (Pubitemid 26097194)
55. N. Kimura, R. Matsuo, H. Shibuya, K. Nakashima, and T. Taga: BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6. J Biol Chem 275, 17647-17652 (2000) (Pubitemid 30430812)
56. T. Moriguchi, N. Kuroyanagi, K. Yamaguchi, Y. Gotoh, K. Irie, T. Kano, K. Shirakabe, Y. Muro, H. Shibuya, K. Matsumoto, E. Nishida, and M. Hagiwara: A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3. J Biol Chem 271, 13675-13679 (1996) (Pubitemid 26187979)
57. T. Ishitani, J. Ninomiya-Tsuji, S. Nagai, M. Nishita, M. Meneghini, N. Barker, M. Waterman, B. Bowerman, H. Clevers, H. Shibuya, and K. Matsumoto: The TAK1-NLKMAPK-related pathway antagonizes signaling between beta-catenin and transcription factor TCF. Nature 399, 798-802 (1999) (Pubitemid 29293177)
58. S.W. Lee, S.I. Han, H.H. Kim, and Z.H. Lee: TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by receptor activator of NF-kappaB. J Biochem Mol Biol 35, 371-376 (2002) (Pubitemid 34868675)
59. K. Shirakabe, K. Yamaguchi, H. Shibuya, K. Irie, S. Matsuda, T. Moriguchi, Y. Gotoh, K. Matsumoto, and E. Nishida: TAK1 mediates the ceramide signaling to stressactivated protein kinase/c-Jun N-terminal kinase. J Biol Chem 272, 8141-8144 (1997) (Pubitemid 27147762)
60. E. Canalis, A.N. Economides, and E. Gazzerro: Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24, 218-235 (2003) (Pubitemid 36515285)
61. Y. Re'em-Kalma, T. Lamb, and D. Frank: Competition between noggin and bone morphogenetic protein 4 activities may regulate dorsalization during Xenopus development. Proc Natl Acad Sci U S A 92, 12141-12145 (1995) (Pubitemid 26014026)
62. E. Gazzerro, V. Gangji, and E. Canalis: Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts. J Clin Invest 102, 2106-2114 (1998) (Pubitemid 29018817)
63. L. Ye, J.M. Lewis-Russell, H. Kynaston, and W.G. Jiang: Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists. J Urol 178, 1086-1091 (2007) (Pubitemid 47211048)
64. D. Onichtchouk, Y.G. Chen, R. Dosch, V. Gawantka, H. Delius, J. Massague, and C. Niehrs: Silencing of TGFbeta signaling by the pseudoreceptor BAMBI. Nature 401, 480-485 (1999) (Pubitemid 29470206)
65. L. Grotewold, M. Plum, R. Dildrop, T. Peters, and U. Ruther: Bambi is coexpressed with Bmp-4 during mouse embryogenesis. Mech Dev 100, 327-330 (2001) (Pubitemid 32109343)
66. W. Jin, C. Yun, H.S. Kim, and S.J. Kim: TrkC binds to the bone morphogenetic protein type II receptor to suppress bone morphogenetic protein signaling. Cancer Res 67, 9869-9877 (2007) (Pubitemid 47621235)
67. M. Sammar, S. Stricker, G.C. Schwabe, C. Sieber, A. Hartung, M. Hanke, I. Oishi, J. Pohl, Y. Minami, W. Sebald, S. Mundlos, and P. Knaus: Modulation of GDF5/BRI-b signaling through interaction with the tyrosine kinase receptor Ror2. Genes Cells 9, 1227-1238 (2004) (Pubitemid 39618536)
68. T.A. Samad, A. Rebbapragada, E. Bell, Y. Zhang, Y. Sidis, S.J. Jeong, J.A. Campagna, S. Perusini, D.A. Fabrizio, A.L. Schneyer, H.Y. Lin, A.H. Brivanlou, L. Attisano, and C.J. Woolf: DRAGON, a bone morphogenetic protein co-receptor. J Biol Chem 280, 14122-14129 (2005) (Pubitemid 40517314)
69. J.L. Babitt, Y. Zhang, T.A. Samad, Y. Xia, J. Tang, J.A. Campagna, A.L. Schneyer, C.J. Woolf, and H.Y. Lin: Repulsive guidance molecule (RGMa), a DRAGON homologue, is a bone morphogenetic protein co-receptor. J Biol Chem 280, 29820-29827 (2005) (Pubitemid 41177060)
70. J.L. Babitt, F.W. Huang, D.M. Wrighting, Y. Xia, Y. Sidis, T.A. Samad, J.A. Campagna, R.T. Chung, A.L. Schneyer, C.J. Woolf, N.C. Andrews, and H.Y. Lin: Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 38, 531-539 (2006)
71. R. Schwappacher, J. Weiske, E. Heining, V. Ezerski, B. Marom, Y.I. Henis, O. Huber, and P. Knaus: Novel crosstalk to BMP signaling: cGMP-dependent kinase I modulates BMP receptor and Smad activity. EMBO J 28, 1537-1550 (2009)
72. A. Hata, G. Lagna, J. Massague, and A. Hemmati-Brivanlou: Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev 12, 186-197 (1998) (Pubitemid 28060449)
73. H. Hayashi, S. Abdollah, Y. Qiu, J. Cai, Y.Y. Xu, B.W. Grinnell, M.A. Richardson, J.N. Topper, M.A. Gimbrone, Jr., J.L. Wrana, and D. Falb: The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell 89, 1165-1173 (1997) (Pubitemid 127678749)
74. T. Imamura, M. Takase, A. Nishihara, E. Oeda, J. Hanai, M. Kawabata, and K. Miyazono: Smad6 inhibits signaling by the TGF-beta superfamily. Nature 389, 622-626 (1997) (Pubitemid 27446182)
75. M. Takase, T. Imamura, T.K. Sampath, K. Takeda, H. Ichijo, K. Miyazono, and M. Kawabata: Induction of Smad6 mRNA by bone morphogenetic proteins. Biochem Biophys Res Commun 244, 26-29 (1998) (Pubitemid 28419894)
76. A. Ishisaki, K. Yamato, S. Hashimoto, A. Nakao, K. Tamaki, K. Nonaka, P. ten Dijke, H. Sugino, and T. Nishihara: Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein- and activin-mediated growth arrest and apoptosis in B cells. J Biol Chem 274, 13637-13642 (1999)
77. F. Itoh, H. Asao, K. Sugamura, C.H. Heldin, P. ten Dijke, and S. Itoh: Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. Embo J 20, 4132-4142 (2001) (Pubitemid 32751829)
78. S. Germain, M. Howell, G.M. Esslemont, and C.S. Hill: Homeodomain and winged-helix transcription factors recruit activated Smads to distinct promoter elements via a common Smad interaction motif. Genes Dev 14, 435-451 (2000) (Pubitemid 30131889)
79. M. Cordenonsi, M. Montagner, M. Adorno, L. Zacchigna, G. Martello, A. Mamidi, S. Soligo, S. Dupont, and S. Piccolo: Integration of TGF-beta and Ras/MAPK signaling through p53 phosphorylation. Science 315, 840-843 (2007)
80. K. Miyazono, S. Maeda, and T. Imamura: Coordinate regulation of cell growth and differentiation by TGF-beta superfamily and Runx proteins. Oncogene 23, 4232-4237 (2004) (Pubitemid 38758589)
81. X.H. Feng, X. Lin, and R. Derynck: Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta. EMBO J 19, 5178-5193 (2000)
82. Y. Sano, J. Harada, S. Tashiro, R. Gotoh-Mandeville, T. Maekawa, and S. Ishii: ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling. J Biol Chem 274, 8949-8957 (1999) (Pubitemid 29164697)
83. K. Kurisaki, A. Kurisaki, U. Valcourt, A.A. Terentiev, K. Pardali, P. Ten Dijke, C.H. Heldin, J. Ericsson, and A. Moustakas: Nuclear factor YY1 inhibits transforming growth factor beta- and bone morphogenetic proteininduced cell differentiation. Mol Cell Biol 23, 4494-4510 (2003) (Pubitemid 36734741)
84. K. Miyazono, P. ten Dijke, and C.H. Heldin: TGF-beta signaling by Smad proteins. Adv Immunol 75, 115-157 (2000)
85. S.H. Durand, A. Romeas, M.L. Couble, D. Langlois, J.Y. Li, H. Magloire, F. Bleicher, M.J. Staquet, and J.C. Farges: Expression of the TGF-beta/BMP inhibitor EVI1 in human dental pulp cells. Arch Oral Biol 52, 712-719 (2007) (Pubitemid 46898960)
86. K. Luo, S.L. Stroschein, W. Wang, D. Chen, E. Martens, S. Zhou, and Q. Zhou: The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev 13, 2196-2206 (1999) (Pubitemid 29426725)
87. F.M. Spagnoli and A.H. Brivanlou: The Gata5 target, TGIF2, defines the pancreatic region by modulating BMP signals within the endoderm. Development 135, 451-461 (2008)
88. D. Wotton and J. Massague: Smad transcriptional corepressors in TGF beta family signaling. Curr Top Microbiol Immunol 254, 145-164 (2001)
89. W. Wang, F.V. Mariani, R.M. Harland, and K. Luo: Ski represses bone morphogenic protein signaling in Xenopus and mammalian cells. Proc Natl Acad Sci U S A 97, 14394-14399 (2000) (Pubitemid 32016586)
90. W. Xu, K. Angelis, D. Danielpour, M.M. Haddad, O. Bischof, J. Campisi, E. Stavnezer, and E.E. Medrano: Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factor. Proc Natl Acad Sci U S A 97, 5924-5929 (2000) (Pubitemid 30367500)
91. Y. Yoshida, S. Tanaka, H. Umemori, O. Minowa, M. Usui, N. Ikematsu, E. Hosoda, T. Imamura, J. Kuno, T. Yamashita, K. Miyazono, M. Noda, T. Noda, and T. Yamamoto: Negative regulation of BMP/Smad signaling by Tob in osteoblasts. Cell 103, 1085-1097 (2000) (Pubitemid 32037395)
92. Y. Yoshida, A. von Bubnoff, N. Ikematsu, I.L. Blitz, J.K. Tsuzuku, E.H. Yoshida, H. Umemori, K. Miyazono, T. Yamamoto, and K.W. Cho: Tob proteins enhance inhibitory Smad-receptor interactions to repress BMP signaling. Mech Dev 120, 629-637 (2003)
93. M. Takeda, M. Mizuide, M. Oka, T. Watabe, H. Inoue, H. Suzuki, T. Fujita, T. Imamura, K. Miyazono, and K. Miyazawa: Interaction with Smad4 is indispensable for suppression of BMP signaling by c-Ski. Mol Biol Cell 15, 963-972 (2004) (Pubitemid 38316207)
94. J. Massague and Y.G. Chen: Controlling TGF-beta signaling. Genes Dev 14, 627-644 (2000)
95. X. Liu, Y. Sun, R.A. Weinberg, and H.F. Lodish: Ski/Sno and TGF-beta signaling. Cytokine Growth Factor Rev 12, 1-8 (2001)
96. K. Arora and R. Warrior: A new Smurf in the village. Dev Cell 1, 441-442 (2001)
97. H. Zhu, P. Kavsak, S. Abdollah, J.L. Wrana, and G.H. Thomsen: A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 400, 687-693 (1999)
98. G. Murakami, T. Watabe, K. Takaoka, K. Miyazono, and T. Imamura: Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. Mol Biol Cell 14, 2809-2817 (2003) (Pubitemid 36871523)
99. H. Kaneki, R. Guo, D. Chen, Z. Yao, E.M. Schwarz, Y.E. Zhang, B.F. Boyce, and L. Xing: Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem 281, 4326-4333 (2006) (Pubitemid 43847863)
100. T. Ebisawa, M. Fukuchi, G. Murakami, T. Chiba, K. Tanaka, T. Imamura, and K. Miyazono: Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem 276, 12477-12480 (2001)
101. D. Koinuma, M. Shinozaki, A. Komuro, K. Goto, M. Saitoh, A. Hanyu, M. Ebina, T. Nukiwa, K. Miyazawa, T. Imamura, and K. Miyazono: Arkadia amplifies TGF-beta superfamily signaling through degradation of Smad7. EMBO J 22, 6458-6470 (2003) (Pubitemid 38009594)
102. G. Kuratomi, A. Komuro, K. Goto, M. Shinozaki, K. Miyazawa, K. Miyazono, and T. Imamura: NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factorbeta) signaling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor. Biochem J 386, 461-470 (2005) (Pubitemid 40445870)
103. S.J. Wicks, K. Haros, M. Maillard, L. Song, R.E. Cohen, P.T. Dijke, and A. Chantry: The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-beta signaling. Oncogene 24, 8080-8084 (2005) (Pubitemid 41746751)
104. L. Ye, J.M. Lewis-Russell, H. Kynaston, and W.G. Jiang: Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol Histopathol in press, (2007)
105. L. Ye, S.M. Bokobza, and W.G. Jiang: Bone morphogenetic proteins in development and progression of breast cancer and therapeutic potential (review). Int J Mol Med 24, 591-597 (2009)
106. H. Bentley, F.C. Hamdy, K.A. Hart, J.M. Seid, J.L. Williams, D. Johnstone, and R.G. Russell: Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 66, 1159-1163 (1992) (Pubitemid 23006160)
107. J. Barnes, C.T. Anthony, N. Wall, and M.S. Steiner: Bone morphogenetic protein-6 expression in normal and malignant prostate. World J Urol 13, 337-343 (1995)
108. F.C. Hamdy, P. Autzen, M.C. Robinson, C.H. Horne, D.E. Neal, and C.N. Robson: Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res 57, 4427-4431 (1997) (Pubitemid 27413455)
109. H. Tamada, R. Kitazawa, K. Gohji, and S. Kitazawa: Epigenetic regulation of human bone morphogenetic protein 6 gene expression in prostate cancer. J Bone Miner Res 16, 487-496 (2001) (Pubitemid 32173363)
110. S.E. Harris, M.A. Harris, P. Mahy, J. Wozney, J.Q. Feng, and G.R. Mundy: Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 24, 204-211 (1994) (Pubitemid 24122069)
111. R. Thomas, L.D. True, P.H. Lange, and R.L. Vessella: Placental bone morphogenetic protein (PLAB) gene expression in normal, pre-malignant and malignant human prostate: relation to tumor development and progression. Int J Cancer 93, 47-52 (2001) (Pubitemid 32539500)
112. L.G. Horvath, S.M. Henshall, J.G. Kench, J.J. Turner, D. Golovsky, P.C. Brenner, G.F. O'Neill, R. Kooner, P.D. Stricker, J.J. Grygiel, and R.L. Sutherland: Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate 59, 234-242 (2004) (Pubitemid 38509755)
113. H. Masuda, Y. Fukabori, K. Nakano, N. Shimizu, and H. Yamanaka: Expression of bone morphogenetic protein-7 (BMP-7) in human prostate. Prostate 59, 101-106 (2004) (Pubitemid 38387847)
114. L. Ye, H. Kynaston, and W.G. Jiang: Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Mol Cancer Res 6, 1594-1606 (2008)
115. L. Ye, H. Kynaston, and W.G. Jiang: Bone morphogenetic protein-10 suppresses the growth and aggressiveness of prostate cancer cells through a Smad independent pathway. J Urol 181, 2749-2759 (2009)
116. I.Y. Kim, D.H. Lee, H.J. Ahn, H. Tokunaga, W. Song, L.M. Devereaux, D. Jin, T.K. Sampath, and R.A. Morton: Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues. Cancer Res 60, 2840-2844 (2000) (Pubitemid 30395803)
117. I.Y. Kim, D.H. Lee, D.K. Lee, H.J. Ahn, M.M. Kim, S.J. Kim, and R.A. Morton: Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 23, 7651-7659 (2004) (Pubitemid 39424923)
118. H. Ide, M. Katoh, H. Sasaki, T. Yoshida, K. Aoki, Y. Nawa, Y. Osada, T. Sugimura, and M. Terada: Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and its expression in prostate cancer in comparison with other BMPRs. Oncogene 14, 1377-1382 (1997) (Pubitemid 27151995)
119. S.R. Davies, G. Watkins, A. Douglas-Jones, R.E. Mansel, and W.G. Jiang: Bone morphogenetic proteins 1 to 7 in human breast cancer, expression pattern and clinical/prognostic relevance. J Exp Ther Oncol 7, 327-338 (2008)
120. S. Hanavadi, T.A. Martin, G. Watkins, R.E. Mansel, and W.G. Jiang: The role of growth differentiation factor-9 (GDF-9) and its analog, GDF-9b/BMP-15, in human breast cancer. Ann Surg Oncol 14, 2159-2166 (2007) (Pubitemid 46988265)
121. J. Li, L. Ye, C. Parr, A. Douglas-Jones, H.G. Kyanaston, R.E. Mansel, and W.G. Jiang: The aberrant expression of bone morphogenetic protein 12 (BMP-12) in human breast cancer and its potential prognostic value. Gene Ther Mol Biol 13, 186-193 (2009)
122. J.H. Clement, J. Sanger, and K. Hoffken: Expression of bone morphogenetic protein 6 in normal mammary tissue and breast cancer cell lines and its regulation by epidermal growth factor. Int J Cancer 80, 250-256 (1999) (Pubitemid 29001729)
123. M.M. Reinholz, S.J. Iturria, J.N. Ingle, and P.C. Roche: Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR. Breast Cancer Res Treat 74, 255-269 (2002) (Pubitemid 34848353)
124. J.T. Buijs, N.V. Henriquez, P.G. van Overveld, G. van der Horst, I. Que, R. Schwaninger, C. Rentsch, P. Ten Dijke, A.M. Cleton-Jansen, K. Driouch, R. Lidereau, R. Bachelier, S. Vukicevic, P. Clezardin, S.E. Papapoulos, M.G. Cecchini, C.W. Lowik, and G. van der Pluijm: Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 67, 8742-8751 (2007) (Pubitemid 47437450)
125. D. Bobinac, I. Maric, S. Zoricic, J. Spanjol, G. Dordevic, E. Mustac, and Z. Fuckar: Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer. Croat Med J 46, 389-396 (2005) (Pubitemid 40686482)
126. M. Raida, J.H. Clement, K. Ameri, C. Han, R.D. Leek, and A.L. Harris: Expression of bone morphogenetic protein 2 in breast cancer cells inhibits hypoxic cell death. Int J Oncol 26, 1465-1470 (2005)
127. E.L. Alarmo, J. Rauta, P. Kauraniemi, R. Karhu, T. Kuukasjarvi, and A. Kallioniemi: Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer. Genes Chromosomes Cancer 45, 411-419 (2006) (Pubitemid 43346773)
128. E.L. Alarmo, T. Kuukasjarvi, R. Karhu, and A. Kallioniemi: A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7. Breast Cancer Res Treat 103, 239-246 (2007) (Pubitemid 46789146)
129. M.W. Helms, J. Packeisen, C. August, B. Schittek, W. Boecker, B.H. Brandt, and H. Buerger: First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptorpositive breast cancer. J Pathol 206, 366-376 (2005) (Pubitemid 40903201)
130. S. Bokobza, L. Ye, H. Kynaston, R.E. Mansel, and W.G. Jiang: Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells. Cancer Genomics Proteomics in press, (2009)
131. Y. Katsuno, A. Hanyu, H. Kanda, Y. Ishikawa, F. Akiyama, T. Iwase, E. Ogata, S. Ehata, K. Miyazono, and T. Imamura: Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene 27, 6322-6333 (2008)
132. K.D. Brubaker, E. Corey, L.G. Brown, and R.L. Vessella: Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem 91, 151-160 (2004)
133. N. Ghosh-Choudhury, G. Ghosh-Choudhury, A. Celeste, P.M. Ghosh, M. Moyer, S.L. Abboud, and J. Kreisberg: Bone morphogenetic protein-2 induces cyclin kinase inhibitor p21 and hypophosphorylation of retinoblastoma protein in estradiol-treated MCF-7 human breast cancer cells. Biochim Biophys Acta 1497, 186-196 (2000) (Pubitemid 30618830)
134. N. Ghosh-Choudhury, K. Woodruff, W. Qi, A. Celeste, S.L. Abboud, and G. Ghosh Choudhury: Bone morphogenetic protein-2 blocks MDA MB 231 human breast cancer cell proliferation by inhibiting cyclindependent kinase-mediated retinoblastoma protein phosphorylation. Biochem Biophys Res Commun 272, 705-711 (2000) (Pubitemid 30420703)
135. F. Pouliot and C. Labrie: Role of Smad1 and Smad4 proteins in the induction of p21WAF1,Cip1 during bone morphogenetic protein-induced growth arrest in human breast cancer cells. J Endocrinol 172, 187-198 (2002) (Pubitemid 34082957)
136. D.R. Haudenschild, S.M. Palmer, T.A. Moseley, Z. You, and A.H. Reddi: Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer. Cancer Res 64, 8276-8284 (2004) (Pubitemid 39491765)
137. J. Du, S. Yang, Z. Wang, C. Zhai, W. Yuan, R. Lei, J. Zhang, and T. Zhu: Bone morphogenetic protein 6 inhibit stress-induced breast cancer cells apoptosis via both Smad and p38 pathways. J Cell Biochem 103, 1584-1597 (2008) (Pubitemid 351490724)
138. M. Takahashi, F. Otsuka, T. Miyoshi, H. Otani, J. Goto, M. Yamashita, T. Ogura, H. Makino, and H. Doihara: Bone morphogenetic protein 6 (BMP6) and BMP7 inhibit estrogen-induced proliferation of breast cancer cells by suppressing p38 mitogen-activated protein kinase activation. J Endocrinol 199, 445-455 (2008)
139. R. Montesano, R. Sarkozi, and H. Schramek: Bone morphogenetic protein-4 strongly potentiates growth factor-induced proliferation of mammary epithelial cells. Biochem Biophys Res Commun 374, 164-168 (2008)
140. E.L. Alarmo, J. Parssinen, J.M. Ketolainen, K. Savinainen, R. Karhu, and A. Kallioniemi: BMP7 influences proliferation, migration, and invasion of breast cancer cells. Cancer Lett 275, 35-43 (2009)
141. H. Miyazaki, T. Watabe, T. Kitamura, and K. Miyazono: BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells. Oncogene 23, 9326-9335 (2004) (Pubitemid 40069665)
142. F. Pouliot, A. Blais, and C. Labrie: Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. Cancer Res 63, 277-281 (2003) (Pubitemid 36152479)
143. N. Dumont and C.L. Arteaga: A kinase-inactive type II TGFbeta receptor impairs BMP signaling in human breast cancer cells. Biochem Biophys Res Commun 301, 108-112 (2003) (Pubitemid 36268855)
144. S.M. Bokobza, L. Ye, H.E. Kynaston, R.E. Mansel, and W.G. Jiang: Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells. Cancer Genomics Proteomics 6, 101-108 (2009)
145. H. Ide, T. Yoshida, N. Matsumoto, K. Aoki, Y. Osada, T. Sugimura, and M. Terada: Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 57, 5022-5027 (1997) (Pubitemid 27498113)
146. T.B. Ro, R.U. Holt, A.T. Brenne, H. Hjorth-Hansen, A. Waage, O. Hjertner, A. Sundan, and M. Borset: Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 23, 3024-3032 (2004) (Pubitemid 38648193)
147. O. Korchynskyi, K.J. Dechering, A.M. Sijbers, W. Olijve, and P. ten Dijke: Gene array analysis of bone morphogenetic protein type I receptor-induced osteoblast differentiation. J Bone Miner Res 18, 1177-1185 (2003) (Pubitemid 37294910)
148. S. Buckley, W. Shi, B. Driscoll, A. Ferrario, K. Anderson, and D. Warburton: BMP4 signaling induces senescence and modulates the oncogenic phenotype of A549 lung adenocarcinoma cells. Am J Physiol Lung Cell Mol Physiol 286, L81-86 (2004) (Pubitemid 38055861)
149. A.R. Hallahan, J.I. Pritchard, R.A. Chandraratna, R.G. Ellenbogen, J.R. Geyer, R.P. Overland, A.D. Strand, S.J. Tapscott, and J.M. Olson: BMP-2 mediates retinoidinduced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med 9, 1033-1038 (2003) (Pubitemid 37021783)
150. J. Xu, T.R. Kimball, J.N. Lorenz, D.A. Brown, A.R. Bauskin, R. Klevitsky, T.E. Hewett, S.N. Breit, and J.D. Molkentin: GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98, 342-350 (2006)
151. O. Hjertner, H. Hjorth-Hansen, M. Borset, C. Seidel, A. Waage, and A. Sundan: Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood 97, 516-522 (2001) (Pubitemid 32060339)
152. S. Yang, C. Zhong, B. Frenkel, A.H. Reddi, and P. Roy-Burman: Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res 65, 5769-5777 (2005) (Pubitemid 40911180)
153. S. Yang, M. Lim, L.K. Pham, S.E. Kendall, A.H. Reddi, D.C. Altieri, and P. Roy-Burman: Bone morphogenetic protein 7 protects prostate cancer cells from stress-induced apoptosis via both Smad and c-Jun NH2-terminal kinase pathways. Cancer Res 66, 4285-4290 (2006)
154. J.H. Clement, N. Marr, A. Meissner, M. Schwalbe, W. Sebald, K.O. Kliche, K. Hoffken, and S. Wolfl: Bone morphogenetic protein 2 (BMP-2) induces sequential changes of Id gene expression in the breast cancer cell line MCF-7. J Cancer Res Clin Oncol 126, 271-279 (2000) (Pubitemid 30246248)
155. S. Steinert, T.C. Kroll, I. Taubert, L. Pusch, P. Hortschansky, K. Hoffken, S. Wolfl, and J.H. Clement: Differential expression of cancer-related genes by single and permanent exposure to bone morphogenetic protein 2. J Cancer Res Clin Oncol 134, 1237-1245 (2008)
156. J.P. Thiery and J.P. Sleeman: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7, 131-142 (2006) (Pubitemid 43278296)
157. Y. Nakajima, T. Yamagishi, S. Hokari, and H. Nakamura: Mechanisms involved in valvuloseptal endocardial cushion formation in early cardiogenesis: roles of transforming growth factor (TGF)-beta and bone morphogenetic protein (BMP). Anat Rec 258, 119-127 (2000) (Pubitemid 30082904)
158. L.A. Romano and R.B. Runyan: Slug is an essential target of TGFbeta2 signaling in the developing chicken heart. Dev Biol 223, 91-102 (2000) (Pubitemid 30439521)
159. M. Zeisberg, A.A. Shah, and R. Kalluri: Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem 280, 8094-8100 (2005) (Pubitemid 40349708)
160. M. Zeisberg, J. Hanai, H. Sugimoto, T. Mammoto, D. Charytan, F. Strutz, and R. Kalluri: BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9, 964-968 (2003) (Pubitemid 36889942)
161. R. Montesano: Bone morphogenetic protein-4 abrogates lumen formation by mammary epithelial cells and promotes invasive growth. Biochem Biophys Res Commun 353, 817-822 (2007) (Pubitemid 46048745)
162. E. Piek, A. Moustakas, A. Kurisaki, C.H. Heldin, and P. ten Dijke: TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci 112 ( Pt 24), 4557-4568 (1999) (Pubitemid 30034805)
163. S. Yang, J. Du, Z. Wang, W. Yuan, Y. Qiao, M. Zhang, J. Zhang, S. Gao, J. Yin, B. Sun, and T. Zhu: BMP-6 promotes E-cadherin expression through repressing deltaEF1 in breast cancer cells. BMC Cancer 7, 211 (2007)
164. M. Kowanetz, U. Valcourt, R. Bergstrom, C.H. Heldin, and A. Moustakas: Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein. Mol Cell Biol 24, 4241-4254 (2004) (Pubitemid 41070996)
165. T. Ogata, J.M. Wozney, R. Benezra, and M. Noda: Bone morphogenetic protein 2 transiently enhances expression of a gene, Id (inhibitor of differentiation), encoding a helix-loop-helix molecule in osteoblast-like cells. Proc Natl Acad Sci U S A 90, 9219-9222 (1993) (Pubitemid 23306484)
166. E.M. Langenfeld, Y. Kong, and J. Langenfeld: Bone morphogenetic protein-2-induced transformation involves the activation of mammalian target of rapamycin. Mol Cancer Res 3, 679-684 (2005) (Pubitemid 43042997)
167. E.M. Langenfeld, S.E. Calvano, F. Abou-Nukta, S.F. Lowry, P. Amenta, and J. Langenfeld: The mature bone morphogenetic protein-2 is aberrantly expressed in nonsmall cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 24, 1445-1454 (2003) (Pubitemid 37160834)
168. T. Rothhammer, I. Poser, F. Soncin, F. Bataille, M. Moser, and A.K. Bosserhoff: Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 65, 448-456 (2005)
169. J.H. Clement, M. Raida, J. Sanger, R. Bicknell, J. Liu, A. Naumann, A. Geyer, A. Waldau, P. Hortschansky, A. Schmidt, K. Hoffken, S. Wolft, and A.L. Harris: Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. Int J Oncol 27, 401-407 (2005)
170. A. Scherberich, R.P. Tucker, M. Degen, M. Brown-Luedi, A.C. Andres, and R. Chiquet-Ehrismann: Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-alpha induced expression in vitro. Oncogene 24, 1525-1532 (2005) (Pubitemid 40396082)
171. O. Gautschi, C.G. Tepper, P.R. Purnell, Y. Izumiya, C.P. Evans, T.P. Green, P.Y. Desprez, P.N. Lara, D.R. Gandara, P.C. Mack, and H.J. Kung: Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res 68, 2250-2258 (2008) (Pubitemid 351521798)
172. B.T. Feeley, S.C. Gamradt, W.K. Hsu, N. Liu, L. Krenek, P. Robbins, J. Huard, and J.R. Lieberman: Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 20, 2189-2199 (2005) (Pubitemid 41698782)
173. J. Dai, J. Keller, J. Zhang, Y. Lu, Z. Yao, and E.T. Keller: Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 65, 8274-8285 (2005) (Pubitemid 41330592)
174. B.T. Feeley, L. Krenek, N. Liu, W.K. Hsu, S.C. Gamradt, E.M. Schwarz, J. Huard, and J.R. Lieberman: Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 38, 154-166 (2006) (Pubitemid 43165781)
175. N. Johansson, U. Saarialho-Kere, K. Airola, R. Herva, L. Nissinen, J. Westermarck, E. Vuorio, J. Heino, and V.M. Kahari: Collagenase-3 (MMP-13) is expressed by hypertrophic chondrocytes, periosteal cells, and osteoblasts during human fetal bone development. Dev Dyn 208, 387-397 (1997) (Pubitemid 27114291)
176. R. Thomas, W.A. Anderson, V. Raman, and A.H. Reddi: Androgen-dependent gene expression of bone morphogenetic protein 7 in mouse prostate. Prostate 37, 236-245 (1998) (Pubitemid 28524656)
177. M. Zhang, Q. Wang, W. Yuan, S. Yang, X. Wang, J.D. Yan, J. Du, J. Yin, S.Y. Gao, B.C. Sun, and T.H. Zhu: Epigenetic regulation of bone morphogenetic protein-6 gene expression in breast cancer cells. J Steroid Biochem Mol Biol 105, 91-97 (2007) (Pubitemid 47211944)
178. M. Schwalbe, J. Sanger, R. Eggers, A. Naumann, A. Schmidt, K. Hoffken, and J.H. Clement: Differential expression and regulation of bone morphogenetic protein 7 in breast cancer. Int J Oncol 23, 89-95 (2003)
179. A. van den Wijngaard, W.R. Mulder, R. Dijkema, C.J. Boersma, S. Mosselman, E.J. van Zoelen, and W. Olijve: Antiestrogens specifically up-regulate bone morphogenetic protein-4 promoter activity in human osteoblastic cells. Mol Endocrinol 14, 623-633 (2000) (Pubitemid 32260507)
180. T. Yamamoto, F. Saatcioglu, and T. Matsuda: Crosstalk between bone morphogenic proteins and estrogen receptor signaling. Endocrinology 143, 2635-2642 (2002) (Pubitemid 34701327)
181. L. Wu, Y. Wu, B. Gathings, M. Wan, X. Li, W. Grizzle, Z. Liu, C. Lu, Z. Mao, and X. Cao: Smad4 as a transcription corepressor for estrogen receptor alpha. J Biol Chem 278, 15192-15200 (2003) (Pubitemid 36799854)
182. S. Kitazawa, R. Kitazawa, C. Obayashi, and T. Yamamoto: Desmoid tumor with ossification in chest wall: possible involvement of BAMBI promoter hypermethylation in metaplastic bone formation. J Bone Miner Res 20, 1472-1477 (2005) (Pubitemid 41033531)
183. X.Z. Wen, Y. Akiyama, S.B. Baylin, and Y. Yuasa: Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. Oncogene 25, 2666-2673 (2006)
184. R.P. Nacamuli, K.D. Fong, K.A. Lenton, H.M. Song, T.D. Fang, A. Salim, and M.T. Longaker: Expression and possible mechanisms of regulation of BMP3 in rat cranial sutures. Plast Reconstr Surg 116, 1353-1362 (2005) (Pubitemid 41456507)
185. H.G. van der Poel, C. Hanrahan, H. Zhong, and J.W. Simons: Rapamycin induces Smad activity in prostate cancer cell lines. Urol Res 30, 380-386 (2003) (Pubitemid 36285655)
186. L. Ye, J.M. Lewis-Russell, A.J. Sanders, H. Kynaston, and W.G. Jiang: HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells. Urol Oncol 26, 190-197 (2008) (Pubitemid 351288565)
187. L. Ye, J.M. Lewis-Russell, G. Davies, A.J. Sanders, H. Kynaston, and W.G. Jiang: Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells. Int J Oncol 30, 521-529 (2007)
188. A.H. Reddi, D. Roodman, C. Freeman, and S. Mohla: Mechanisms of tumor metastasis to the bone: challenges and opportunities. J Bone Miner Res 18, 190-194 (2003) (Pubitemid 36125910)
189. M.B. Choueiri, S.M. Tu, L.Y. Yu-Lee, and S.H. Lin: The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Rev 25, 601-609 (2006) (Pubitemid 46071866)
190. L. Ye, H.G. Kynaston, and W.G. Jiang: Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review). Int J Mol Med 20, 103-111 (2007)
191. Y. Takuwa, T. Masaki, and K. Yamashita: The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochem Biophys Res Commun 170, 998-1005 (1990) (Pubitemid 20273366)
192. J.B. Nelson, S.P. Hedican, D.J. George, A.H. Reddi, S. Piantadosi, M.A. Eisenberger, and J.W. Simons: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1, 944-949 (1995)
193. S. Granchi, S. Brocchi, L. Bonaccorsi, E. Baldi, M.C. Vinci, G. Forti, M. Serio, and M. Maggi: Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate 49, 267-277 (2001) (Pubitemid 33117002)
194. J.J. Yin, K.S. Mohammad, S.M. Kakonen, S. Harris, J.R. Wu-Wong, J.L. Wessale, R.J. Padley, I.R. Garrett, J.M. Chirgwin, and T.A. Guise: A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 100, 10954-10959 (2003) (Pubitemid 37140134)
195. M.A. Carducci, R.J. Padley, J. Breul, N.J. Vogelzang, B.A. Zonnenberg, D.D. Daliani, C.C. Schulman, A.A. Nabulsi, R.A. Humerickhouse, M.A. Weinberg, J.L. Schmitt, and J.B. Nelson: Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21, 679-689 (2003) (Pubitemid 46621903)
196. G.A. Clines, K.S. Mohammad, Y. Bao, O.W. Stephens, L.J. Suva, J.D. Shaughnessy, Jr., J.W. Fox, J.M. Chirgwin, and T.A. Guise: Dickkopf Homolog 1 Mediates Endothelin-1-Stimulated New Bone Formation*. Mol Endocrinol (2006)
197. J.B. Nelson, K. Chan-Tack, S.P. Hedican, S.R. Magnuson, T.J. Opgenorth, G.S. Bova, and J.W. Simons: Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 56, 663-668 (1996) (Pubitemid 26059878)
198. M. Mehrotra, S.M. Krane, K. Walters, and C. Pilbeam: Differential regulation of platelet-derived growth factor stimulated migration and proliferation in osteoblastic cells. J Cell Biochem 93, 741-752 (2004) (Pubitemid 44264170)
199. B. Yi, P.J. Williams, M. Niewolna, Y. Wang, and T. Yoneda: Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 62, 917-923 (2002) (Pubitemid 34126973)
200. C.R. Dunstan, R. Boyce, B.F. Boyce, I.R. Garrett, E. Izbicka, W.H. Burgess, and G.R. Mundy: Systemic administration of acidic fibroblast growth factor (FGF-1) prevents bone loss and increases new bone formation in ovariectomized rats. J Bone Miner Res 14, 953-959 (1999) (Pubitemid 29262890)
201. J.M. Chan, M.J. Stampfer, E. Giovannucci, P.H. Gann, J. Ma, P. Wilkinson, C.H. Hennekens, and M. Pollak: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279, 563-566 (1998) (Pubitemid 28067285)
202. S.F. Shariat, D.J. Lamb, M.W. Kattan, C. Nguyen, J. Kim, J. Beck, T.M. Wheeler, and K.M. Slawin: Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 20, 833-841 (2002) (Pubitemid 34111393)
203. J.M. Chan, M.J. Stampfer, J. Ma, P. Gann, J.M. Gaziano, M. Pollak, and E. Giovannucci: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94, 1099-1106 (2002) (Pubitemid 34830730)
204. J. Rubin, X. Fan, J. Rahnert, B. Sen, C.L. Hsieh, T.C. Murphy, M.S. Nanes, L.G. Horton, W.G. Beamer, and C.J. Rosen: IGF-I secretion by prostate carcinoma cells does not alter tumor-bone cell interactions in vitro or in vivo. Prostate 66, 789-800 (2006)
205. H.P. Gerber, T.H. Vu, A.M. Ryan, J. Kowalski, Z. Werb, and N. Ferrara: VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5, 623-628 (1999) (Pubitemid 29289424)
206. J. Street, M. Bao, L. deGuzman, S. Bunting, F.V. Peale, Jr., N. Ferrara, H. Steinmetz, J. Hoeffel, J.L. Cleland, A. Daugherty, N. van Bruggen, H.P. Redmond, R.A. Carano, and E.H. Filvaroff: Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A 99, 9656-9661 (2002) (Pubitemid 34831103)
207. V. Midy and J. Plouet: Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochem Biophys Res Commun 199, 380-386 (1994) (Pubitemid 24179960)
208. J. Dai, Y. Kitagawa, J. Zhang, Z. Yao, A. Mizokami, S. Cheng, J. Nor, L.K. McCauley, R.S. Taichman, and E.T. Keller: Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 64, 994-999 (2004) (Pubitemid 38176902)
209. J. Chen, S. De, J. Brainard, and T.V. Byzova: Metastatic properties of prostate cancer cells are controlled by VEGF. Cell Commun Adhes 11, 1-11 (2004) (Pubitemid 39069726)
210. T. Krupski, M.A. Harding, M.E. Herce, K.M. Gulding, M.H. Stoler, and D. Theodorescu: The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells. Growth Factors 18, 287-302 (2001) (Pubitemid 32776308)
211. G. Chen, N. Shukeir, A. Potti, K. Sircar, A. Aprikian, D. Goltzman, and S.A. Rabbani: Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101, 1345-1356 (2004) (Pubitemid 39180390)
212. C.L. Hall, S. Kang, O.A. MacDougald, and E.T. Keller: Role of Wnts in prostate cancer bone metastases. J Cell Biochem 97, 661-672 (2006)
213. E. Tian, F. Zhan, R. Walker, E. Rasmussen, Y. Ma, B. Barlogie, and J.D. Shaughnessy, Jr.: The role of the Wntsignaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349, 2483-2494 (2003) (Pubitemid 38010074)
214. K.D. Schluter, C. Katzer, and H.M. Piper: A Nterminal PTHrP peptide fragment void of a PTH/PTHrPreceptor binding domain activates cardiac ET(A) receptors. Br J Pharmacol 132, 427-432 (2001) (Pubitemid 32142355)
215. S.D. Cramer, Z. Chen, and D.M. Peehl: Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrPstimulated cAMP accumulation in mouse osteoblasts. J Urol 156, 526-531 (1996) (Pubitemid 126445373)
216. A. Achbarou, S. Kaiser, G. Tremblay, L.G. Ste-Marie, P. Brodt, D. Goltzman, and S.A. Rabbani: Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54, 2372-2377 (1994) (Pubitemid 24138727)
217. S.A. Rabbani, J. Desjardins, A.W. Bell, D. Banville, A. Mazar, J. Henkin, and D. Goltzman: An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 173, 1058-1064 (1990)
218. M. Koutsilieris: Osteoblastic metastasis in advanced prostate cancer. Anticancer Res 13, 443-449 (1993) (Pubitemid 23196786)
219. C.S. Killian, D.A. Corral, E. Kawinski, and R.I. Constantine: Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 192, 940-947 (1993) (Pubitemid 23227414)
220. P. Cohen, H.C. Graves, D.M. Peehl, M. Kamarei, L.C. Giudice, and R.G. Rosenfeld: Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75, 1046-1053 (1992)
221. P. Cohen, D.M. Peehl, H.C. Graves, and R.G. Rosenfeld: Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 142, 407-415 (1994) (Pubitemid 24285445)
222. F. Vakar-Lopez, C.J. Cheng, J. Kim, G.G. Shi, P. Troncoso, S.M. Tu, L.Y. Yu-Lee, and S.H. Lin: Upregulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol 203, 688-695 (2004) (Pubitemid 38714106)
223. A.K. Liang, J. Liu, S.A. Mao, V.S. Siu, Y.C. Lee, and S.H. Lin: Expression of recombinant MDA-BF-1 with a kinase recognition site and a 7-histidine tag for receptor binding and purification. Protein Expr Purif 44, 58-64 (2005) (Pubitemid 41405936)
224. G.D. Roodman: Mechanisms of bone metastasis. N Engl J Med 350, 1655-1664 (2004)
225. G.J. Powell, J. Southby, J.A. Danks, R.G. Stillwell, J.A. Hayman, M.A. Henderson, R.C. Bennett, and T.J. Martin: Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 51, 3059-3061 (1991)
226. R.J. Thomas, T.A. Guise, J.J. Yin, J. Elliott, N.J. Horwood, T.J. Martin, and M.T. Gillespie: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140, 4451-4458 (1999) (Pubitemid 30666108)
227. J. de la Mata, H.L. Uy, T.A. Guise, B. Story, B.F. Boyce, G.R. Mundy, and G.D. Roodman: Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 95, 2846-2852 (1995)
228. N. Kurihara, D. Bertolini, T. Suda, Y. Akiyama, and G.D. Roodman: IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol 144, 4226-4230 (1990) (Pubitemid 20187761)
229. F. Basolo, L. Fiore, G. Fontanini, P.G. Conaldi, S. Calvo, V. Falcone, and A. Toniolo: Expression of and response to interleukin 6 (IL6) in human mammary tumors. Cancer Res 56, 3118-3122 (1996) (Pubitemid 26199759)
230. J.Y. Blay, S. Schemann, and M.C. Favrot: Local production of interleukin 6 by renal adenocarcinoma in vivo. J Natl Cancer Inst 86, 238 (1994)
231. S.S. Tabibzadeh, D. Poubouridis, L.T. May, and P.B. Sehgal: Interleukin-6 immunoreactivity in human tumors. Am J Pathol 135, 427-433 (1989) (Pubitemid 19246200)
232. W. Thabard, M. Collette, M.P. Mellerin, D. Puthier, S. Barille, R. Bataille, and M. Amiot: IL-6 upregulates its own receptor on some human myeloma cell lines. Cytokine 14, 352-356 (2001) (Pubitemid 32730477)
233. K. Ono, T. Akatsu, T. Murakami, R. Kitamura, M. Yamamoto, N. Shinomiya, M. Rokutanda, T. Sasaki, N. Amizuka, H. Ozawa, N. Nagata, and N. Kugai: Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J Bone Miner Res 17, 774-781 (2002) (Pubitemid 34441893)
234. L. Pederson, B. Winding, N.T. Foged, T.C. Spelsberg, and M.J. Oursler: Identification of breast cancer cell linederived paracrine factors that stimulate osteoclast activity. Cancer Res 59, 5849-5855 (1999)
235. A.T. Mancino, V.S. Klimberg, M. Yamamoto, S.C. Manolagas, and E. Abe: Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 100, 18-24 (2001) (Pubitemid 32807701)
236. E. Sapi: The role of CSF-1 in normal physiology of mammary gland and breast cancer: an update. Exp Biol Med (Maywood) 229, 1-11 (2004) (Pubitemid 38101673)
237. O.V. Batson: The function of the vertebral veins and their role in the spread of metastases. 1940. Clin Orthop Relat Res 4-9 (1995)
238. A.C. Khodavirdi, Z. Song, S. Yang, C. Zhong, S. Wang, H. Wu, C. Pritchard, P.S. Nelson, and P. Roy-Burman: Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res 66, 883-888 (2006) (Pubitemid 43165954)
239. K. Fizazi, J. Yang, S. Peleg, C.R. Sikes, E.L. Kreimann, D. Daliani, M. Olive, K.A. Raymond, T.J. Janus, C.J. Logothetis, G. Karsenty, and N.M. Navone: Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 9, 2587-2597 (2003) (Pubitemid 36842101)
240. K. Jacob, M. Webber, D. Benayahu, and H.K. Kleinman: Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res 59, 4453-4457 (1999) (Pubitemid 29418768)
241. J.H. Zhang, J. Tang, J. Wang, W. Ma, W. Zheng, T. Yoneda, and J. Chen: Over-expression of bone sialoprotein enhances bone metastasis of human breast cancer cells in a mouse model. Int J Oncol 23, 1043-1048 (2003)
242. D.T. Denhardt, C.M. Giachelli, and S.R. Rittling: Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 41, 723-749 (2001) (Pubitemid 32385904)
243. T.J. Rosol: Pathogenesis of bone metastases: role of tumor-related proteins. J Bone Miner Res 15, 844-850 (2000) (Pubitemid 30233407)
244. A.M. Moursi, C.H. Damsky, J. Lull, D. Zimmerman, S.B. Doty, S. Aota, and R.K. Globus: Fibronectin regulates calvarial osteoblast differentiation. J Cell Sci 109 ( Pt 6), 1369-1380 (1996) (Pubitemid 26190487)
245. A.M. Moursi, R.K. Globus, and C.H. Damsky: Interactions between integrin receptors and fibronectin are required for calvarial osteoblast differentiation in vitro. J Cell Sci 110 ( Pt 18), 2187-2196 (1997) (Pubitemid 27448363)
246. R.K. Globus, S.B. Doty, J.C. Lull, E. Holmuhamedov, M.J. Humphries, and C.H. Damsky: Fibronectin is a survival factor for differentiated osteoblasts. J Cell Sci 111 ( Pt 10), 1385-1393 (1998) (Pubitemid 28274390)
247. J.D. Termine, H.K. Kleinman, S.W. Whitson, K.M. Conn, M.L. McGarvey, and G.R. Martin: Osteonectin, a bone-specific protein linking mineral to collagen. Cell 26, 99-105 (1981) (Pubitemid 12229368)
248. A.M. Delany, M. Amling, M. Priemel, C. Howe, R. Baron, and E. Canalis: Osteopenia and decreased bone formation in osteonectin-deficient mice. J Clin Invest 105, 915-923 (2000) (Pubitemid 30203064)
249. P. Bornstein, L.C. Armstrong, K.D. Hankenson, T.R. Kyriakides, and Z. Yang: Thrombospondin 2, a matricellular protein with diverse functions. Matrix Biol 19, 557-568 (2000)
250. K.D. Hankenson and P. Bornstein: The secreted protein thrombospondin 2 is an autocrine inhibitor of marrow stromal cell proliferation. J Bone Miner Res 17, 415-425 (2002) (Pubitemid 34171756)
251. K.D. Hankenson, I.E. James, S. Apone, G.B. Stroup, S.M. Blake, X. Liang, M.W. Lark, and P. Bornstein: Increased osteoblastogenesis and decreased bone resorption protect against ovariectomy-induced bone loss in thrombospondin-2- null mice. Matrix Biol 24, 362-370 (2005) (Pubitemid 41021639)
252. N. Thapa, K.B. Kang, and I.S. Kim: Beta ig-h3 mediates osteoblast adhesion and inhibits differentiation. Bone 36, 232-242 (2005) (Pubitemid 40283580)
253. J. Skonier, K. Bennett, V. Rothwell, S. Kosowski, G. Plowman, P. Wallace, S. Edelhoff, C. Disteche, M. Neubauer, H. Marquardt, and et al.: beta ig-h3: a transforming growth factor-beta-responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice. DNA Cell Biol 13, 571-584 (1994)
254. P. Ducy, C. Desbois, B. Boyce, G. Pinero, B. Story, C. Dunstan, E. Smith, J. Bonadio, S. Goldstein, C. Gundberg, A. Bradley, and G. Karsenty: Increased bone formation in osteocalcin-deficient mice. Nature 382, 448-452 (1996) (Pubitemid 26264860)
255. G. Luo, P. Ducy, M.D. McKee, G.J. Pinero, E. Loyer, R.R. Behringer, and G. Karsenty: Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386, 78-81 (1997) (Pubitemid 27130923)
256. G.K. Hunter and H.A. Goldberg: Nucleation of hydroxyapatite by bone sialoprotein. Proc Natl Acad Sci U S A 90, 8562-8565 (1993) (Pubitemid 23277709)
257. B. Ganss, R.H. Kim, and J. Sodek: Bone sialoprotein. Crit Rev Oral Biol Med 10, 79-98 (1999) (Pubitemid 29510048)
258. K. Hultenby, F.P. Reinholt, and D. Heinegard: Distribution of integrin subunits on rat metaphyseal osteoclasts and osteoblasts. Eur J Cell Biol 62, 86-93 (1993) (Pubitemid 23324682)
259. F.P. Reinholt, K. Hultenby, A. Oldberg, and D. Heinegard: Osteopontin - a possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A 87, 4473-4475 (1990)
260. M. Ishijima, K. Tsuji, S.R. Rittling, T. Yamashita, H. Kurosawa, D.T. Denhardt, A. Nifuji, and M. Noda: Resistance to unloading-induced three-dimensional bone loss in osteopontin-deficient mice. J Bone Miner Res 17, 661-667 (2002) (Pubitemid 34246641)
261. H. Ihara, D.T. Denhardt, K. Furuya, T. Yamashita, Y. Muguruma, K. Tsuji, K.A. Hruska, K. Higashio, S. Enomoto, A. Nifuji, S.R. Rittling, and M. Noda: Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. J Biol Chem 276, 13065-13071 (2001)
262. M.F. Young: Bone matrix proteins: their function, regulation, and relationship to osteoporosis. Osteoporos Int 14 Suppl 3, S35-42 (2003)
263. S. Wadhwa, M.C. Embree, Y. Bi, and M.F. Young: Regulation, regulatory activities, and function of biglycan. Crit Rev Eukaryot Gene Expr 14, 301-315 (2004) (Pubitemid 40221059)
264. Y. Mochida, D. Parisuthiman, and M. Yamauchi: Biglycan is a positive modulator of BMP-2 induced osteoblast differentiation. Adv Exp Med Biol 585, 101-113 (2006)
265. X.D. Chen, L.W. Fisher, P.G. Robey, and M.F. Young: The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation. Faseb J 18, 948-958 (2004) (Pubitemid 38787591)
266. P. Garnero, N. Buchs, J. Zekri, R. Rizzoli, R.E. Coleman, and P.D. Delmas: Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82, 858-864 (2000) (Pubitemid 30085239)
267. A. Lipton, E. Small, F. Saad, D. Gleason, D. Gordon, M. Smith, L. Rosen, M.O. Kowalski, D. Reitsma, and J. Seaman: The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 20 Suppl 2, 45-54 (2002) (Pubitemid 35303443)
268. Y. Kakehi, T. Segawa, X.X. Wu, P. Kulkarni, R. Dhir, and R.H. Getzenberg: Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia. Prostate 59, 351-356 (2004) (Pubitemid 38661801)
269. H. Masuda, Y. Fukabori, K. Nakano, Y. Takezawa, C.S. T, and H. Yamanaka: Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 54, 268-274 (2003) (Pubitemid 36228163)
270. T.G. Hullinger, R.S. Taichman, D.A. Linseman, and M.J. Somerman: Secretory products from PC-3 and MCF-7 tumor cell lines upregulate osteopontin in MC3T3-E1 cells. Cell Biochem 78, 607-616 (2000) (Pubitemid 30620706)
271. M.J. Goumans, G. Valdimarsdottir, S. Itoh, A. Rosendahl, P. Sideras, and P. ten Dijke: Balancing the activation state of the endothelium via two distinct TGFbeta type I receptors. EMBO J 21, 1743-1753 (2002) (Pubitemid 34614630)
272. C. Regazzoni, K.H. Winterhalter, and L. Rohrer: Type I collagen induces expression of bone morphogenetic protein receptor type II. Biochem Biophys Res Commun 283, 316-322 (2001) (Pubitemid 32924690)
273. T. Nakagawa, J.H. Li, G. Garcia, W. Mu, E. Piek, E.P. Bottinger, Y. Chen, H.J. Zhu, D.H. Kang, G.F. Schreiner, H.Y. Lan, and R.J. Johnson: TGF-beta induces proangiogenic and antiangiogenic factors via parallel but distinct Smad pathways. Kidney Int 66, 605-613 (2004) (Pubitemid 38982002)
274. S.U. Han, H.T. Kim, D.H. Seong, Y.S. Kim, Y.S. Park, Y.J. Bang, H.K. Yang, and S.J. Kim: Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer. Oncogene 23, 1333-1341 (2004) (Pubitemid 38406829)
275. I. Schwarte-Waldhoff, O.V. Volpert, N.P. Bouck, B. Sipos, S.A. Hahn, S. Klein-Scory, J. Luttges, G. Kloppel, U. Graeven, C. Eilert-Micus, A. Hintelmann, and W. Schmiegel: Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci U S A 97, 9624-9629 (2000) (Pubitemid 30650826)
276. H. Yamashita, A. Shimizu, M. Kato, H. Nishitoh, H. Ichijo, A. Hanyu, I. Morita, M. Kimura, F. Makishima, and K. Miyazono: Growth/differentiation factor-5 induces angiogenesis in vivo. Exp Cell Res 235, 218-226 (1997) (Pubitemid 27381700)
277. S. Mori, H. Yoshikawa, J. Hashimoto, T. Ueda, H. Funai, M. Kato, and K. Takaoka: Antiangiogenic agent (TNP-470) inhibition of ectopic bone formation induced by bone morphogenetic protein-2. Bone 22, 99-105 (1998) (Pubitemid 28058499)
278. L.C. Yeh and J.C. Lee: Osteogenic protein-1 increases gene expression of vascular endothelial growth factor in primary cultures of fetal rat calvaria cells. Mol Cell Endocrinol 153, 113-124 (1999) (Pubitemid 29339162)
279. J. Glienke, A.O. Schmitt, C. Pilarsky, B. Hinzmann, B. Weiss, A. Rosenthal, and K.H. Thierauch: Differential gene expression by endothelial cells in distinct angiogenic states. Eur J Biochem 267, 2820-2830 (2000) (Pubitemid 30304280)
280. M.M. Deckers, R.L. van Bezooijen, G. van der Horst, J. Hoogendam, C. van Der Bent, S.E. Papapoulos, and C.W. Lowik: Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 143, 1545-1553 (2002) (Pubitemid 34274386)
281. L.N. Ramoshebi and U. Ripamonti: Osteogenic protein-1, a bone morphogenetic protein, induces angiogenesis in the chick chorioallantoic membrane and synergizes with basic fibroblast growth factor and transforming growth factor-beta1. Anat Rec 259, 97-107 (2000) (Pubitemid 30244075)
282. M. Scharpfenecker, M. van Dinther, Z. Liu, R.L. van Bezooijen, Q. Zhao, L. Pukac, C.W. Lowik, and P. ten Dijke: BMP-9 signals via ALK1 and inhibits bFGFinduced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 120, 964-972 (2007) (Pubitemid 46638511)
283. J.E. Moreau, K. Anderson, J.R. Mauney, T. Nguyen, D.L. Kaplan, and M. Rosenblatt: Tissue-engineered bone serves as a target for metastasis of human breast cancer in a mouse model. Cancer Res 67, 10304-10308 (2007) (Pubitemid 350070804)
284. P. Bunyaratavej, T.G. Hullinger, and M.J. Somerman: Bone morphogenetic proteins secreted by breast cancer cells upregulate bone sialoprotein expression in preosteoblast cells. Exp Cell Res 260, 324-333 (2000)
285. R. Schwaninger, C.A. Rentsch, A. Wetterwald, G. van der Horst, R.L. van Bezooijen, G. van der Pluijm, C.W. Lowik, K. Ackermann, W. Pyerin, F.C. Hamdy, G.N. Thalmann, and M.G. Cecchini: Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. Am J Pathol 170, 160-175 (2007) (Pubitemid 47339197)
286. H. Namkoong, S.M. Shin, H.K. Kim, S.A. Ha, G.W. Cho, S.Y. Hur, T.E. Kim, and J.W. Kim: The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein. BMC Cancer 6, 74 (2006)
287. Y. Katsuno, A. Hanyu, H. Kanda, Y. Ishikawa, F. Akiyama, T. Iwase, E. Ogata, S. Ehata, K. Miyazono, and T. Imamura: Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene 27(49):6322-33. (2008)
288. L. Ye, J.M. Lewis-Russell, H. Kynaston, and W.G. Jiang: Endogenous BMP-7 controls the motility of prostate cancer cells through regulation of BMP Antagonists. J Urol in press, (2007)
289. B.B. Koenig, J.S. Cook, D.H. Wolsing, J. Ting, J.P. Tiesman, P.E. Correa, C.A. Olson, A.L. Pecquet, F. Ventura, R.A. Grant, and et al.: Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells. Mol Cell Biol 14, 5961-5974 (1994) (Pubitemid 24264425)
290. N. Yamaji, A.J. Celeste, R.S. Thies, J.J. Song, S.M. Bernier, D. Goltzman, K.M. Lyons, J. Nove, V. Rosen, and J.M. Wozney: A mammalian serine/threonine kinase receptor specifically binds BMP-2 and BMP-4. Biochem Biophys Res Commun 205, 1944-1951 (1994)
291. M. Namiki, S. Akiyama, T. Katagiri, A. Suzuki, N. Ueno, N. Yamaji, V. Rosen, J.M. Wozney, and T. Suda: A kinase domain-truncated type I receptor blocks bone morphogenetic protein-2-induced signal transduction in C2C12 myoblasts. J Biol Chem 272, 22046-22052 (1997) (Pubitemid 27382829)
292. F. Liu, F. Ventura, J. Doody, and J. Massague: Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol Cell Biol 15, 3479-3486 (1995)
293. A. Daluiski, T. Engstrand, M.E. Bahamonde, L.W. Gamer, E. Agius, S.L. Stevenson, K. Cox, V. Rosen, and K.M. Lyons: Bone morphogenetic protein-3 is a negative regulator of bone density. Nat Genet 27, 84-88 (2001) (Pubitemid 32044524)
294. P. ten Dijke, H. Yamashita, T.K. Sampath, A.H. Reddi, M. Estevez, D.L. Riddle, H. Ichijo, C.H. Heldin, and K. Miyazono: Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J Biol Chem 269, 16985-16988 (1994) (Pubitemid 24204009)
295. T. Nohno, T. Ishikawa, T. Saito, K. Hosokawa, S. Noji, D.H. Wolsing, and J.S. Rosenbaum: Identification of a human type II receptor for bone morphogenetic protein-4 that forms differential heteromeric complexes with bone morphogenetic protein type I receptors. J Biol Chem 270, 22522-22526 (1995)
296. B.L. Rosenzweig, T. Imamura, T. Okadome, G.N. Cox, H. Yamashita, P. ten Dijke, C.H. Heldin, and K. Miyazono: Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc Natl Acad Sci U S A 92, 7632-7636 (1995)
297. H. Aoki, M. Fujii, T. Imamura, K. Yagi, K. Takehara, M. Kato, and K. Miyazono: Synergistic effects of different bone morphogenetic protein type I receptors on alkaline phosphatase induction. J Cell Sci 114, 1483-1489 (2001) (Pubitemid 32427835)
298. V. Zuzarte-Luis, J.A. Montero, J. Rodriguez-Leon, R. Merino, J.C. Rodriguez-Rey, and J.M. Hurle: A new role for BMP5 during limb development acting through the synergic activation of Smad and MAPK pathways. Dev Biol 272, 39-52 (2004) (Pubitemid 38887283)
299. H.N. Beck, K. Drahushuk, D.B. Jacoby, D. Higgins, and P.J. Lein: Bone morphogenetic protein-5 (BMP-5) promotes dendritic growth in cultured sympathetic neurons. BMC Neurosci 2, 12 (2001)
300. N. Ahmed, J. Sammons, R.J. Carson, M.A. Khokher, and H.T. Hassan: Effect of bone morphogenetic protein-6 on haemopoietic stem cells and cytokine production in normal human bone marrow stroma. Cell Biol Int 25, 429-435 (2001) (Pubitemid 32530355)
301. T. Ebisawa, K. Tada, I. Kitajima, K. Tojo, T.K. Sampath, M. Kawabata, K. Miyazono, and T. Imamura: Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. J Cell Sci 112 ( Pt 20), 3519-3527 (1999)
302. S. Mazerbourg, K. Sangkuhl, C.W. Luo, S. Sudo, C. Klein, and A.J. Hsueh: Identification of receptors and signaling pathways for orphan bone morphogenetic protein/growth differentiation factor ligands based on genomic analyses. J Biol Chem 280, 32122-32132 (2005) (Pubitemid 41361818)
303. R.K. Moore, F. Otsuka, and S. Shimasaki: Molecular basis of bone morphogenetic protein-15 signaling in granulosa cells. J Biol Chem 278, 304-310 (2003) (Pubitemid 36043577)
304. S.K. Cheng, F. Olale, J.T. Bennett, A.H. Brivanlou, and A.F. Schier: EGF-CFC proteins are essential coreceptors for the TGF-beta signals Vg1 and GDF1. Genes Dev 17, 31-36 (2003) (Pubitemid 36062505)
305. I. Lopez-Coviella, T.M. Mellott, V.P. Kovacheva, B. Berse, B.E. Slack, V. Zemelko, A. Schnitzler, and J.K. Blusztajn: Developmental pattern of expression of BMP receptors and Smads and activation of Smad1 and Smad5 by BMP9 in mouse basal forebrain. Brain Res 1088, 49-56 (2006) (Pubitemid 43729407)
306. H. Nishitoh, H. Ichijo, M. Kimura, T. Matsumoto, F. Makishima, A. Yamaguchi, H. Yamashita, S. Enomoto, and K. Miyazono: Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5. J Biol Chem 271, 21345-21352 (1996) (Pubitemid 26292996)
307. X. Chen, A. Zankl, F. Niroomand, Z. Liu, H.A. Katus, L. Jahn, and C. Tiefenbacher: Upregulation of ID protein by growth and differentiation factor 5 (GDF5) through a smad-dependent and MAPK-independent pathway in HUVSMC. J Mol Cell Cardiol 41, 26-33 (2006) (Pubitemid 43946963)
308. T. Nakahara, K. Tominaga, T. Koseki, M. Yamamoto, K. Yamato, J. Fukuda, and T. Nishihara: Growth/differentiation factor-5 induces growth arrest and apoptosis in mouse B lineage cells with modulation by Smad. Cell Signal 15, 181-187 (2003) (Pubitemid 35449121)
309. A. Rebbapragada, H. Benchabane, J.L. Wrana, A.J. Celeste, and L. Attisano: Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol Cell Biol 23, 7230-7242 (2003) (Pubitemid 37211004)
310. A.C. McPherron, A.M. Lawler, and S.J. Lee: Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11. Nat Genet 22, 260-264 (1999) (Pubitemid 29297252)
311. S.P. Oh, C.Y. Yeo, Y. Lee, H. Schrewe, M. Whitman, and E. Li: Activin type IIA and IIB receptors mediate Gdf11 signaling in axial vertebral patterning. Genes Dev 16, 2749-2754 (2002) (Pubitemid 35253141)
312. O. Andersson, E. Reissmann, and C.F. Ibanez: Growth differentiation factor 11 signals through the transforming growth factor-beta receptor ALK5 to regionalize the anterior-posterior axis. EMBO Rep 7, 831-837 (2006) (Pubitemid 44275403)
313. R.L. Strausberg, E.A. Feingold, L.H. Grouse, J.G. Derge, R.D. Klausner, F.S. Collins, L. Wagner, C.M. Shenmen, G.D. Schuler, S.F. Altschul, B. Zeeberg, K.H. Buetow, C.F. Schaefer, N.K. Bhat, R.F. Hopkins, H. Jordan, T. Moore, S.I. Max, J. Wang, F. Hsieh, L. Diatchenko, K. Marusina, A.A. Farmer, G.M. Rubin, L. Hong, M. Stapleton, M.B. Soares, M.F. Bonaldo, T.L. Casavant, T.E. Scheetz, M.J. Brownstein, T.B. Usdin, S. Toshiyuki, P. Carninci, C. Prange, S.S. Raha, N.A. Loquellano, G.J. Peters, R.D. Abramson, S.J. Mullahy, S.A. Bosak, P.J. McEwan, K.J. McKernan, J.A. Malek, P.H. Gunaratne, S. Richards, K.C. Worley, S. Hale, A.M. Garcia, L.J. Gay, S.W. Hulyk, D.K. Villalon, D.M. Muzny, E.J. Sodergren, X. Lu, R.A. Gibbs, J. Fahey, E. Helton, M. Ketteman, A. Madan, S. Rodrigues, A. Sanchez, M. Whiting, A.C. Young, Y. Shevchenko, G.G. Bouffard, R.W. Blakesley, J.W. Touchman, E.D. Green, M.C. Dickson, A.C. Rodriguez, J. Grimwood, J. Schmutz, R.M. Myers, Y.S. Butterfield, M.I. Krzywinski, U. Skalska, D.E. Smailus, A. Schnerch, J.E. Schein, S.J. Jones, and M.A. Marra: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A 99, 16899-16903 (2002) (Pubitemid 36034070)
314. E. Ozkaynak, P.N. Schnegelsberg, D.F. Jin, G.M. Clifford, F.D. Warren, E.A. Drier, and H. Oppermann: Osteogenic protein-2. A new member of the transforming growth factor-beta superfamily expressed early in embryogenesis. J Biol Chem 267, 25220-25227 (1992)
315. H. Neuhaus, V. Rosen, and R.S. Thies: Heart specific expression of mouse BMP-10 a novel member of the TGFbeta superfamily. Mech Dev 80, 181-184 (1999) (Pubitemid 29125429)
316. J.L. Dube, P. Wang, J. Elvin, K.M. Lyons, A.J. Celeste, and M.M. Matzuk: The bone morphogenetic protein 15 gene is X-linked and expressed in oocytes. Mol Endocrinol 12, 1809-1817 (1998) (Pubitemid 28544177)
317. C.T. Rankin, T. Bunton, A.M. Lawler, and S.J. Lee: Regulation of left-right patterning in mice by growth/differentiation factor-1. Nat Genet 24, 262-265 (2000) (Pubitemid 30132194)
318. S.J. Lee: Expression of growth/differentiation factor 1 in the nervous system: conservation of a bicistronic structure. Proc Natl Acad Sci U S A 88, 4250-4254 (1991)
319. A.J. Celeste, J.J. Song, K. Cox, V. Rosen, and J.M. Wozney: Bone morphogenetic protein-9, a new member of the TGF-beta superfamily. J Bone Min Res Suppl 1, S136 (1994)
320. A.C. McPherron and S.J. Lee: GDF-3 and GDF-9: two new members of the transforming growth factor-beta superfamily containing a novel pattern of cysteines. J Biol Chem 268, 3444-3449 (1993) (Pubitemid 23070981)
321. M. Ye, K.M. Berry-Wynne, M. Asai-Coakwell, P. Sundaresan, T. Footz, C.R. French, M. Abitbol, V.C. Fleisch, N. Corbett, W.T. Allison, G. Drummond, M.A. Walter, T.M. Underhill, A.J. Waskiewicz, and O.J. Lehmann: Mutation of the bone morphogenetic protein GDF3 causes ocular and skeletal anomalies. Hum Mol Genet 19, 287-298 (2009)
322. O. Andersson, M. Korach-Andre, E. Reissmann, C.F. Ibanez, and P. Bertolino: Growth/differentiation factor 3 signals through ALK7 and regulates accumulation of adipose tissue and diet-induced obesity. Proc Natl Acad Sci U S A 105, 7252-7256 (2008) (Pubitemid 351754464)
323. G. Hotten, H. Neidhardt, B. Jacobowsky, and J. Pohl: Cloning and expression of recombinant human growth/differentiation factor 5. Biochem Biophys Res Commun 204, 646-652 (1994)
324. A.J. Davidson, J.H. Postlethwait, Y.L. Yan, D.R. Beier, C. van Doren, D. Foernzler, A.J. Celeste, K.E. Crosier, and P.S. Crosier: Isolation of zebrafish gdf7 and comparative genetic mapping of genes belonging to the growth/differentiation factor 5, 6, 7 subgroup of the TGFbeta superfamily. Genome Res 9, 121-129 (1999) (Pubitemid 29116859)
325. K.J. Lee, M. Mendelsohn, and T.M. Jessell: Neuronal patterning by BMPs: a requirement for GDF7 in the generation of a discrete class of commissural interneurons in the mouse spinal cord. Genes Dev 12, 3394-3407 (1998) (Pubitemid 28520987)
326. A.C. McPherron, A.M. Lawler, and S.J. Lee: Regulation of skeletal muscle mass in mice by a new TGFbeta superfamily member. Nature 387, 83-90 (1997) (Pubitemid 27202654)
327. N.S. Cunningham, N.A. Jenkins, D.J. Gilbert, N.G. Copeland, A.H. Reddi, and S.J. Lee: Growth/differentiation factor-10: a new member of the transforming growth factor-beta superfamily related to bone morphogenetic protein-3. Growth Factors 12, 99-109 (1995)
328. L.W. Gamer, N.M. Wolfman, A.J. Celeste, G. Hattersley, R. Hewick, and V. Rosen: A novel BMP expressed in developing mouse limb, spinal cord, and tail bud is a potent mesoderm inducer in Xenopus embryos. Dev Biol 208, 222-232 (1999) (Pubitemid 29149460)
329. M. Yokoyama-Kobayashi, M. Saeki, S. Sekine, and S. Kato: Human cDNA encoding a novel TGF-beta superfamily protein highly expressed in placenta. J Biochem (Tokyo) 122, 622-626 (1997) (Pubitemid 27443241)
330. P. Vanhara, E. Lincova, A. Kozubik, P. Jurdic, K. Soucek, and J. Smarda: Growth/differentiation factor-15 inhibits differentiation into osteoclasts - A novel factor involved in control of osteoclast differentiation. Differentiation 78, 213-222 (2009)
331. T. Tanno, N.V. Bhanu, P.A. Oneal, S.H. Goh, P. Staker, Y.T. Lee, J.W. Moroney, C.H. Reed, N.L. Luban, R.H. Wang, T.E. Eling, R. Childs, T. Ganz, S.F. Leitman, S. Fucharoen, and J.L. Miller: High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 13, 1096-1101 (2007) (Pubitemid 47517510)